West Pharmaceutical Services (WST) Q3 2025 10-Q Quarterly Report
Filed: Oct 23, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR West Pharmaceutical Services (WST) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Oct 23, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
West Pharmaceutical Services Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Revenue $805M, up 7.7% YoY ($57.7M increase) for Q3 2025; Proprietary Products $647.5M (+7.7%), Contract-Manufactured Products $157.1M (+8.0%)
- • Operating margin 20.8% vs 21.6% YoY Q3 2025 (down 0.8 pts); adjusted operating margin 21.1% vs 21.5%; gross margin 36.6% vs 35.4% (up 1.2 pts)
- • Best segment: Proprietary Products operating profit up 10.7% YoY Q3 2025 to $175.2M; worst segment: Contract-Manufactured Products operating profit slightly up 2.3% YoY Q3 2025 to $22.3M but down 4.5% YTD
- • Cash and equivalents rose to $628.5M (Sept 30, 2025) from $484.6M (Dec 31, 2024); operating cash flow $503.7M for 9 months ended Sept 30, 2025, up $40.4M YoY; share repurchases $134M in 9 months 2025 vs higher in 2024
- • Management expects no material impact from tariffs or geopolitical risks; operating profit growth continues but corporate expenses and restructuring charges increased; outlook cautious on cost pressures and maintaining production efficiency
Risk Factors
- • Continued COVID-19 impact on supply chain and customer demand remains key operational risk
- • Exposure to foreign currency fluctuations affecting reported results due to international sales
- • New product development and regulatory approval delays could impact near-term competitive position
- • Ongoing legal proceedings related to patent disputes involving product portfolio risks compliance
- • Debt maturities concentrated in 2026 require cash flow management to mitigate financial liquidity risk
West Pharmaceutical Services Q3 2025 Quarterly FinancialsXBRL
Revenue
$805M
▲ +7.7% YoY▲ +5.0% QoQ
Net Income
$140M
▲ +2.9% YoY▲ +6.2% QoQ
Net Margin
17.4%
▼ -81bp YoY▲ +20bp QoQ
Source: XBRL data from West Pharmaceutical Services Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on West Pharmaceutical Services
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.